Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm phase 3 study of Cobenfy for cognitive impairment in adults with schizophrenia
MOH_2025-12-11_015530Phase 3Not yet recruiting
- Sponsor
- European Group for Research in Schizophrenia
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trospium in schizophrenia, sponsored by European Group for Research in Schizophrenia. Primary endpoint: Change in BACS score from baseline to week 24. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
trospium
03
Conditions
schizophrenia
Beyond the preview
Go deeper on MOH_2025-12-11_015530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-11_015530.